ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 506

Clinical and Sonographic Characteristics of Carotid Intima-Media Thickness in Rheumatoid Arthritis Patients

José R. Azpiri-López1, Iris J. Colunga-Pedraza2, Estefania E. Abundis-Marquez3, Jose A. Davila-Jimenez3, Andres H. Guillen-Lozoya3, Raymundo Vera-Pineda3, Jesus A. Cardenas-de la Garza3, Adrián Martínez-Moreno3, Rosa I. Arvizu-Rivera3, Francisco J. Torres-Quintanilla3, Aldo Valdovinos-Bañuelos3, Ray Ramos-Cázares3, Cinthia Y. Guillen-Gutierrez3, Guillermo Elizondo-Riojas3, Dionisio Castillo-Ortiz4 and Dionicio A. Galarza-Delgado5, 1Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, 2Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, 3Hospital Universitario, UANL, Monterrey, Mexico, 4Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, 5Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

 

Clinical and Sonographic Characteristics of Carotid Intima-media Thickness in Rheumatoid arthritis patients

Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic disease with high cardiovascular (CV) risk. Carotid intima media thickness (CIMT) is an independent surrogate marker of subclinical atherosclerosis. Several instruments may underestimate CV risk in RA (1). Objectives: to describe demographic and clinical characteristics, CV risks and carotid ultrasound(US) measurements ; to assess the differences among three RA-groups according to CIMT and to assess the usefulness of CV risk scores as predictors of higher CIMT.

Methods: All patients fulfilled 1987 ACR and/or 2010 ACR/EULAR classification criteria. Subjects between 40-75 years old were included. CV risk was calculated by seven scales. Carotid US was performed by a board-certified radiologist and reviewed by two radiologists. Carotid plaque (CP) = CIMT ³0.12 cm or a ³50% focal increase of CIMT compared to the surrounding normal arterial wall. Three RA-groups were created according to CIMT.

Results: One hundred RA-patients were included, demographic data are in figure 1. CIMT: 25 had <0.079 cm (group 1), 38 had 0.08-0.09 cm (group 2) and 37 had CIMT ³ 0.09 cm (group 3). Six scores had statistically significant result. The highest sensitivity to detect increased CIMT was obtained by SCORE-moderate risk (75.7%) and the highest specificity was 100% with Framingham-lipids-high risk.

Conclusion: CIMT can be used as an independent surrogate marker of subclinical atherosclerosis in RA-patients. Different CV risk scores did not predict the presence of CP.

Reference: 1) Galarza-Delgado DA., et al. "Assessment of six cardiovascular risk calculators in Mexican mestizo patients with rheumatoid arthritis according to the EULAR 2015/2016 recommendations for cardiovascular risk management." Clinical rheumatology 36.6 (2017):1387-1393.

 

 

 

 

Figure 1. Baseline characteristics

A.

 

CIMT ² 0.079 cm

(n=25)

CIMT  0.08-0.09 cm

(n=38)

CIMT ³ 0.1 cm

(n=37)

P

Age,years, mean ± SD

53.1± 8.1)

54.2 ± 8.7

61.5 ± 6.9

<0.01

 Women, n (%)

24 (96)

37 (97)

35 (95)

NS

Body mass Index,kg/m2, mean ± SD

28.8  ± 5.5

28.4 ± 5.6

29.6 ± 5.0

NS

Disease variables

 

 

 

 

Disease duration, years, mean ± SD

12.8 ± 9.7

14.8 ± 7.5

12.9 ± 8.7

NS

Diagnosis delay, months,

median (Percentile 25-75)

7.1 (2.0-24.3)

5.0 (2.1-36.5)

12.2 (5.0-12.4)

NS

CRP, mg/L, median (Percentile 25-75)

0.7 (0.5-1.0)

1.0 (0.6-1.3)

0.9 (0.6-1.1)

NS

ESR mm/H , median (Percentile 25-75)

34 (15-44)

21 (13-32)

24 (14-36)

NS

RF IgG, IU/ml, median (Percentile 25-75)

6.8 (0-24.9)

8.6 (5.3-13.1)

9.5 (3.9-18.1)

NS

RF IgM, IU/ml, median (Percentile 25-75)

163.3 (54.7-200)

76.6 (35.2-200)

194.3 (56.8-200)

NS

RF IgA, IU/ml, median (Percentiles 25-75)

34.1 (14-135)

39.4 (11.5-93.5)

59.5 (18.5-179)

NS

antiCCP, U/ml, median (Percentiles 25-75)

85.9 (2.6-198)

27.2 (4-197)

106.7 (4.4-196)

NS

DAS28-CRP, mean ± SD

3.4 ± 1.2

3.2 ± 1.2

3.2 ±1.4

NS

CDAI, mean ± SD

16.6 ± 12.5

12.5 ± 10.0

13.1 ± 12.1

NS

SDAI, mean ± SD

17.5 ± 12.5

13.5 ± 10.1

13.9 ± 12.2

NS

Methotrexate user, n(%)

23 (92)

37 (77)

21 (78)

NS

Prednisone user, n(%)

18 (72)

23 (48)

14 (52)

NS

Cardiovascular risk calculator

 

 

 

 

OMNIBUS, mean (SD)

2.1 ± 2.2

3.7 ± 3.7

8.8 ± 8.1

<0.01

FRS-Lipids, mean ± SD

4.2 ± 2.8

6.5 ± 4.7

11.2 ± 9.6

<0.01

FRS-BMI, mean ± SD

6.5 ± 4.7

9.6 ± 8.0

15.7 ± 12.7

<0.01

SCORE, mean ± SD

0.5 ± 1.0

0.7 ± 0.9

1.7 ± 1.4

<0.01

ERS-RA, mean ± SD

5.7 ± 4.2

8.3 ± 7.6

10.8 ± 7.8

NS

QRISKII, mean ± SD

4.4 ± 3.7

7.0 ± 5.7

13.7 ± 8.7

<0.01

RRS, mean ± SD

1.5 ± 1.1

2.4 ± 2.1

5.0 ± 5.5

<0.01

 

Ultrasound Variables

 

 

 

 

Plaque, n (%)

0

6 (13)

7 (26)

<0.01

Bilateral plaque, n (%)

0

0

16 (59)

<0.01

CIMT,mm, mean ± SD

0.06 ± 0.01

0.08 ± 0.01

0.1 ± 0.08

<0.01

 

B.

CV risk

CIMT <0.09

CIMT >0.09

Total

Sensitivity

Specificity

PPV

NPV

OMNIBUS, high risk,

6

14

20

37.8

90.5

70

71.3

FRS-Lipids, high risk, n(%)

0

3

3

8.1

100

100

64.9

FRS-BMI, high risk, n (%)

6

8

14

21.6

90.5

57.1

66.3

SCORE, moderate risk, n(%)

24

28

56

75.7

61.9

53.8

81.3

RRS, moderate and High, n (%)

1

3

4

8.1

98.4

75

64.6

CRP = C-reactive protein;  ESR = erytrocyte sedimentation rate; RF = Rheumatoid Factor;  antiCCP = Anti-cyclic citrullinated peptide; DAS28-CRP = disease activity score; CDAI = Clinical Disease Activity; CDAI = Clinical Disease Activity Index; SDAI = Simplified Disease Activity Index; ACC-AHA 2013 = THe American College of Cardiology and American Heart AssociationÕs 2013; FRS-lipids = Framingham Risk Score using lipids; FRS-BMI = Framingham Risk Score using lipids; SCORE = Systemic Coronary Risk Evaluation; ERS-RA = Extended Risk Score-Rheumatoid Arthritis; RRS = Reynolds Risk Score; CIMT = Carotid Intima-Media Thickness ;PPV = Positive Predictive Value ; NPV =  Negative Predictive Value.

 


Disclosure: J. R. Azpiri-López, None; I. J. Colunga-Pedraza, None; E. E. Abundis-Marquez, None; J. A. Davila-Jimenez, None; A. H. Guillen-Lozoya, None; R. Vera-Pineda, None; J. A. Cardenas-de la Garza, None; A. Martínez-Moreno, None; R. I. Arvizu-Rivera, None; F. J. Torres-Quintanilla, None; A. Valdovinos-Bañuelos, None; R. Ramos-Cázares, None; C. Y. Guillen-Gutierrez, None; G. Elizondo-Riojas, None; D. Castillo-Ortiz, None; D. A. Galarza-Delgado, None.

To cite this abstract in AMA style:

Azpiri-López JR, Colunga-Pedraza IJ, Abundis-Marquez EE, Davila-Jimenez JA, Guillen-Lozoya AH, Vera-Pineda R, Cardenas-de la Garza JA, Martínez-Moreno A, Arvizu-Rivera RI, Torres-Quintanilla FJ, Valdovinos-Bañuelos A, Ramos-Cázares R, Guillen-Gutierrez CY, Elizondo-Riojas G, Castillo-Ortiz D, Galarza-Delgado DA. Clinical and Sonographic Characteristics of Carotid Intima-Media Thickness in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/clinical-and-sonographic-characteristics-of-carotid-intima-media-thickness-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-sonographic-characteristics-of-carotid-intima-media-thickness-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology